PE20040722A1 - Formas cristalinas del acido 3-metiltiofen-2-carboxilico - Google Patents

Formas cristalinas del acido 3-metiltiofen-2-carboxilico

Info

Publication number
PE20040722A1
PE20040722A1 PE2003000741A PE2003000741A PE20040722A1 PE 20040722 A1 PE20040722 A1 PE 20040722A1 PE 2003000741 A PE2003000741 A PE 2003000741A PE 2003000741 A PE2003000741 A PE 2003000741A PE 20040722 A1 PE20040722 A1 PE 20040722A1
Authority
PE
Peru
Prior art keywords
methylthiophen
crystalline forms
carboxyl acid
refers
same
Prior art date
Application number
PE2003000741A
Other languages
English (en)
Spanish (es)
Inventor
Guido Jordine
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040722A1 publication Critical patent/PE20040722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PE2003000741A 2002-07-29 2003-07-25 Formas cristalinas del acido 3-metiltiofen-2-carboxilico PE20040722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0217504.0A GB0217504D0 (en) 2002-07-29 2002-07-29 Organic compounds

Publications (1)

Publication Number Publication Date
PE20040722A1 true PE20040722A1 (es) 2004-11-29

Family

ID=9941275

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000741A PE20040722A1 (es) 2002-07-29 2003-07-25 Formas cristalinas del acido 3-metiltiofen-2-carboxilico

Country Status (30)

Country Link
US (1) US7683048B2 (enExample)
EP (2) EP1554303B1 (enExample)
JP (1) JP2006501207A (enExample)
KR (1) KR100688371B1 (enExample)
CN (1) CN1305892C (enExample)
AR (1) AR040692A1 (enExample)
AT (1) ATE349459T1 (enExample)
AU (1) AU2003251651B2 (enExample)
BR (1) BR0313044A (enExample)
CA (1) CA2493330C (enExample)
CY (1) CY1106406T1 (enExample)
DE (1) DE60310747T2 (enExample)
DK (1) DK1554303T3 (enExample)
EC (1) ECSP055579A (enExample)
ES (1) ES2279970T3 (enExample)
GB (1) GB0217504D0 (enExample)
HK (1) HK1080484B (enExample)
IL (2) IL166287A0 (enExample)
MX (1) MXPA05001173A (enExample)
MY (1) MY136407A (enExample)
NO (1) NO20050806L (enExample)
NZ (2) NZ537868A (enExample)
PE (1) PE20040722A1 (enExample)
PL (1) PL209409B1 (enExample)
PT (1) PT1554303E (enExample)
RU (2) RU2348646C1 (enExample)
SI (1) SI1554303T1 (enExample)
TW (1) TWI309164B (enExample)
WO (1) WO2004013156A1 (enExample)
ZA (1) ZA200500370B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0603783D0 (en) * 2006-02-24 2006-04-05 Novartis Ag Organic compounds
CN103622962A (zh) * 2008-03-14 2014-03-12 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的纤维症的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU550939A1 (ru) * 1975-05-19 1994-07-15 Институт химии древесины АН ЛатвССР 1,2,3,4,4а,4в,5,6,10,10а -декагидро -6- хлорацетоксиметил -1,4а-диметил -7- (1-метилэтил) -1- фенантренкарбоновая кислота или ее соли
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TWI309164B (en) 2009-05-01
CN1671731A (zh) 2005-09-21
HK1080484A1 (en) 2006-04-28
EP1554303B1 (en) 2006-12-27
PL209409B1 (pl) 2011-08-31
RU2330043C2 (ru) 2008-07-27
NZ537868A (en) 2006-11-30
US7683048B2 (en) 2010-03-23
PT1554303E (pt) 2007-03-30
MXPA05001173A (es) 2005-05-16
IL184848A0 (en) 2007-12-03
JP2006501207A (ja) 2006-01-12
ES2279970T3 (es) 2007-09-01
GB0217504D0 (en) 2002-09-04
DK1554303T3 (da) 2007-04-30
ZA200500370B (en) 2006-07-26
NO20050806L (no) 2005-02-15
CA2493330A1 (en) 2004-02-12
DE60310747D1 (en) 2007-02-08
CY1106406T1 (el) 2011-10-12
CA2493330C (en) 2011-08-23
AR040692A1 (es) 2005-04-13
NZ549713A (en) 2008-04-30
EP1554303A1 (en) 2005-07-20
IL166287A0 (en) 2006-01-15
HK1080484B (en) 2007-08-03
DE60310747T2 (de) 2007-10-11
ECSP055579A (es) 2005-04-18
KR100688371B1 (ko) 2007-03-02
BR0313044A (pt) 2005-06-14
CN1305892C (zh) 2007-03-21
WO2004013156A1 (en) 2004-02-12
MY136407A (en) 2008-09-30
EP1676854A1 (en) 2006-07-05
AU2003251651B2 (en) 2007-07-12
AU2003251651A1 (en) 2004-02-23
TW200401633A (en) 2004-02-01
RU2007143025A (ru) 2009-01-20
RU2005105688A (ru) 2005-10-10
US20060166954A1 (en) 2006-07-27
PL373140A1 (en) 2005-08-22
ATE349459T1 (de) 2007-01-15
KR20050033632A (ko) 2005-04-12
SI1554303T1 (sl) 2007-06-30
RU2348646C1 (ru) 2009-03-10

Similar Documents

Publication Publication Date Title
PE20040722A1 (es) Formas cristalinas del acido 3-metiltiofen-2-carboxilico
EE200300171A (et) Kristalliline monohüdraat, meetodid selle valmistamiseks ja selle kasutamine farmatseutilise kompositsiooni valmistamiseks
NO329884B1 (no) Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
ATE337793T1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
CA2274074A1 (en) Novel compounds with analgesic effect
CA2514224A1 (en) Liquid pharmaceutical formulations of palonosetron
ATE395044T1 (de) Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EE200100007A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
IT8848730A0 (it) Derivati 17beta-oh 19-nor steroidei sostituiti in 17alfa, procedimento di preparazione, loro impiego come medicamenti e composizioni farmaceutiche che li compongono
EE200100559A (et) Atsetüülsalitsüülhapet ja klopidogreelvesiniksulfaati sisaldav farmatseutiline kompositsioon üksikannusvormis
DE60022188D1 (de) Amorphe salpetersäureester und deren pharmazeutische zusammensetzungen
AU2003243719A1 (en) Topical administration of pharmacologically active bases in the treatment of warts
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
CA2396111A1 (en) Substances for use in treating psoriasis
EE200200057A (et) Kasvutegurit IL-5 pärssiv asauratsiilderivaat, selle saamine ja kasutamine ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
EE200100051A (et) Vastavast (-)-stereoisomeerist põhiliselt vaba (+)-nortsisapriidi või selle farmatseutiliselt vastuvõetava soola kasutamine ja farmatseutiline kompositsioon
AR035553A1 (es) Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.
AR033331A1 (es) Formas polimorfas de un citrato de azabiciclo [2,2,2] octan-3-amina, sus composiciones farmaceuticas, procedimiento de tratamiento y procedimiento para su produccion.
ATE290543T1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
GEP20043300B (en) Amorphous Torasemide Modification
AR015190A1 (es) Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
DK1590317T3 (da) Enantiomerren (4S,8S)- og (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecandisyre og dennes derivater, fremgangsmåde til disses fremstilling og anvendelse til fremstilling af farmaceutiske midler
IT1245371B (it) Derivati di flavoni, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
FC Refusal